- Home
- GNTA vs BOLD Comparison
GNTA vs BOLD Comparison
Compare GNTA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNTA | BOLD |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 26.2M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GNTA | BOLD |
|---|---|---|
| Price | $1.61 | $1.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 100.5K | ★ 185.6K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $1.00 |
| 52 Week High | $10.00 | $3.45 |
Technical Indicators
Market Signals| Indicator | GNTA | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 49.33 |
| Support Level | $1.80 | $1.11 |
| Resistance Level | $2.07 | $1.20 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 85.00 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.